Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach
Esophageal Cancer, Gastric Cancer
About this trial
This is an interventional treatment trial for Esophageal Cancer focused on measuring stage II gastric cancer, stage III gastric cancer, stage II esophageal cancer, stage III esophageal cancer, adenocarcinoma of the stomach, adenocarcinoma of the esophagus
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically proven adenocarcinoma of the esophagus, gastroesophageal junction or cardia T2N1, T3 any N, T4 any N, and negative margins Proximal and distal margins of resection must be negative No metastases Must be within 4-12 weeks from date of surgery and clinically without evidence of local-regional or distant recurrence PATIENT CHARACTERISTICS: Age: 18 and over Performance Status: ECOG 0-1 Life Expectancy: Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count at least 120,000/mm3 Hepatic: SGOT no greater than 2 times upper limit of normal (ULN) Bilirubin no greater than 2 times ULN Renal: Creatinine within institutional normal limits Cardiovascular: No New York Heart Association class III or IV heart disease No symptomatic coronary artery disease No myocardial infarction within 6 months No clinically significant conduction system abnormalities such as second or third degree heart block or bundle branch block Neurologic: No symptomatic peripheral neuropathy No psychosis Other: Not pregnant or nursing Effective contraceptive method must be used by fertile patients No significant hearing loss No concurrent uncontrolled infection or medical illness No concurrent malignancies within 3 years, except: Nonmelanoma skin cancer Carcinoma in situ of the cervix No history of allergy to drugs containing cremophor No hypersensitivity to E. coli derived proteins PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No prior chemotherapy No other concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics
Sites / Locations
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
- Veterans Affairs Medical Center - Chicago (Lakeside)
- CCOP - Evanston
- CCOP - Illinois Oncology Research Association
- CCOP - Central Illinois
- CCOP - Carle Cancer Center
- CCOP - Cedar Rapids Oncology Project
- CCOP - Ochsner
- New England Medical Center Hospital
- Beth Israel Deaconess Medical Center
- CCOP - Ann Arbor Regional
- CCOP - Metro-Minnesota
- CCOP - Northern New Jersey
- Albert Einstein Comprehensive Cancer Center
- Veterans Affairs Medical Center - New York
- Kaplan Cancer Center
- CCOP - Merit Care Hospital
- Ireland Cancer Center
- CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center
- Allegheny University Hospitals- Hahnemann
- University of Pennsylvania Cancer Center
- Fox Chase Cancer Center
- University of Pittsburgh Cancer Institute
- CCOP - MainLine Health
- Veterans Affairs Medical Center - Madison
- University of Wisconsin Comprehensive Cancer Center
- Medical College of Wisconsin
- Veterans Affairs Medical Center - Milwaukee (Zablocki)
- Veterans Affairs Medical Center - San Juan
- Pretoria Academic Hospital